| Dec'17 | Dec'16 | |||||
|---|---|---|---|---|---|---|
Revenues | ||||||
48,052 | 28,990 | |||||
Cost of sales | ||||||
36,632 | 22,995 | |||||
Gross profit | ||||||
11,420 | 5,995 | |||||
Operating expenses | ||||||
Selling, general and administrative expenses | ||||||
13,742 | 10,825 | |||||
Research and product development expenses | ||||||
6,376 | 3,576 | |||||
Total operating expenses | ||||||
20,118 | 14,401 | |||||
Gain (loss) from operations | ||||||
-8,698 | -8,406 | |||||
Finance income (loss) | ||||||
Interest expense, net | ||||||
-1,812 | -1,762 | |||||
Foreign currency gains (losses), net | ||||||
635 | -268 | |||||
Loss from joint ventures | ||||||
-334 | -156 | |||||
Other finance gains (losses), net | ||||||
-931 | 735 | |||||
Finance income (loss), net | ||||||
-2,442 | -1,451 | |||||
Income (loss) before income taxes | ||||||
-11,140 | -9,857 | |||||
Income tax expense | ||||||
0 | 0 | |||||
Net loss for the period | ||||||
-11,140 | -9,857 | |||||
Items that will not be reclassified subsequently to net loss: | ||||||
Re-measurement of actuarial liability | ||||||
98 | -101 | |||||
Items that may be reclassified subsequently to net loss | ||||||
Exchange differences on translating foreign operations | ||||||
1,703 | -298 | |||||
Comprehensive loss for the period | ||||||
-9,339 | -10,256 | |||||
Net loss per share | ||||||
Basic and diluted | ||||||
-0.80 | -0.79 | |||||
Weighted average number of common shares outstanding | ||||||
13,947 | 12,542 | |||||